Metabolic Health Meets Oncology: GLP-1 Receptor Agonists in Breast Cancer

As GLP-1 receptor agonists surge in popularity for obesity and diabetes, how do they actually impact breast cancer biology, treatment safety, and patient survivorship? In this interview, Dr. Jasmin Hundal discusses her co-authored review published in JCO Oncology Practice, exploring the metabolic, clinical, and survivorship implications of GLP-1 receptor agonists in breast cancer. She examines the biological links between adipose dysfunction and tumor progression, the clinical risk of sarcopenic muscle loss, and why enthusiasm from retrospective headlines must be balanced with prospective evidence. Read the full accompanying article on Oncology Data Advisor: https://bit.ly/4eyjjfM What You’ll Learn in This Episode: 🔹 Answering Daily Patient Inquiries: Evaluating the safety, drug interactions, and monitoring requirements when patients use GLP-1 therapies alongside chemotherapy or endocrine therapy. 🔹 Biological Interplay of Adiposity & Tumorigenesis: How metabolically dysfunctional adipose tissue drives estrogen production, insulin/IGF-1 signaling, chronic inflammation, and pathways relevant to breast cancer like PIK3CA. 🔹 Guarding Against Sarcopenia & Functional Decline: Why cancer-associated weight loss must not sacrifice lean muscle mass, which is directly tied to treatment toxicity, dose reductions, and worse outcomes. 🔹 Lifestyle & Nutritional Countermeasures: Prioritizing adequate protein intake, resistance training, and nutritional status to protect muscle preservation and maintain treatment tolerance. 🔹 Distinguishing Media Headlines from Prospective Proof: Why current recurrence and survival claims stem from retrospective database studies, and what prospective trials are needed to validate direct oncologic benefits. 🔹 The Emergence of Metabo-Oncology: Viewing host metabolism not as background medical history, but as an active driver intersecting cancer biology, therapy tolerance, and survivorship.